Kato, Shumei
Kurzrock, Razelle http://orcid.org/0000-0003-4110-1214
Article History
First Online: 9 November 2018
Competing interests
: R.K. receives research funding from Genentech, Incyte, Merck, Serono, Pfizer, Sequenom, Foundation Medicine, Konica Minolta, Grifols and Guardant, as well as receiving consultant fees from Loxo, X Biotech, NeoMed and Actuate Therapeutics, receiving speaker fees from Roche, and holding an ownership interest in IDbyDNA and Curematch Inc.